fluconazole has been researched along with ganciclovir in 22 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (27.27) | 18.2507 |
| 2000's | 5 (22.73) | 29.6817 |
| 2010's | 10 (45.45) | 24.3611 |
| 2020's | 1 (4.55) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Balzarini, J; De Clercq, E; Judge, V; Kumar, P; Narang, R; Narasimhan, B; Sharma, D | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Bellera, CL; Bruno-Blanch, LE; Castro, EA; Duchowicz, PR; Goodarzi, M; Ortiz, EV; Pesce, G; Talevi, A | 1 |
| Annand, R; Gozalbes, R; Jacewicz, M; Pineda-Lucena, A; Tsaioun, K | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Balzarini, J; De Clercq, E; Karki, SS; Kulkarni, AA; Kumar, S; Veliyath, SK | 1 |
| Hughes, WT | 1 |
| Bianchi Porro, G; Cernuschi, M; Lazzarin, A; Parente, F; Rizzardini, G; Valsecchi, L | 1 |
| Gill, SK | 1 |
| Stratta, RJ | 1 |
| Bajew, L; Czekalski, S; Kozioł, L; Roszkowiak, B; Wanic-Kossowska, M | 1 |
| Cheng, B | 1 |
| Alvarez Grande, J; de Oña, M; Fresno, MF; Gómez, E; Herreros, M; Melón, S; Navascués, R; Tricas, L | 1 |
| Bastide, C; Bruyère, F; Chandenier, J; Desoubeaux, G; Fourcade, C; Guy, L; Karsenty, G; Lachaud, L; Lavigne, JP; Malavaud, S; Sotto, A | 1 |
| Monk, HM; Wade, KC | 1 |
| Abdul-Aziz, MH; Dhanani, JA; Lipman, J; Livermore, A; Pincus, J; Roberts, JA; Townsend, S; Wallis, SC | 1 |
4 review(s) available for fluconazole and ganciclovir
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
New drugs for infections in patients with cancer.
Topics: 4-Quinolones; Animals; Anti-Infective Agents; Bacterial Infections; Cytomegalovirus Infections; Fluconazole; Ganciclovir; Humans; Mycoses; Neoplasms | 1992 |
[Non-antibiotic anti-infectious treatments in urology].
Topics: Acyclovir; Albendazole; Amphotericin B; Anti-Infective Agents; Caspofungin; Cidofovir; Cytosine; Echinocandins; Fluconazole; Flucytosine; Foscarnet; Ganciclovir; Humans; Ivermectin; Lipopeptides; Organophosphonates; Praziquantel; Urologic Diseases; Valganciclovir | 2013 |
New antifungal and antiviral dosing.
Topics: Acyclovir; Amphotericin B; Antifungal Agents; Antiviral Agents; Candidiasis, Invasive; Cytomegalovirus Infections; Deoxycholic Acid; Drug Combinations; Fluconazole; Ganciclovir; Herpes Simplex; Humans; Infant; Infant, Newborn; Mycoses; Practice Guidelines as Topic; Pregnancy Complications, Infectious; Valganciclovir; Virus Diseases | 2015 |
18 other study(ies) available for fluconazole and ganciclovir
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Synthesis, antimicrobial and antiviral evaluation of substituted imidazole derivatives.
Topics: Animals; Anti-Bacterial Agents; Antifungal Agents; Antiviral Agents; Aspergillus niger; Bacillus subtilis; Candida albicans; Cells, Cultured; Chlorocebus aethiops; Drug Design; Escherichia coli; HeLa Cells; Herpesvirus 1, Human; Humans; Imidazoles; Microbial Sensitivity Tests; Molecular Structure; Staphylococcus aureus; Stereoisomerism; Structure-Activity Relationship; Vero Cells | 2009 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Prediction of drug intestinal absorption by new linear and non-linear QSPR.
Topics: Humans; Intestinal Absorption; Linear Models; Molecular Conformation; Nonlinear Dynamics; Permeability; Pharmaceutical Preparations; Probability; Quantitative Structure-Activity Relationship; Thermodynamics | 2011 |
QSAR-based permeability model for drug-like compounds.
Topics: Caco-2 Cells; Cell Membrane Permeability; Drug Discovery; Humans; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2011 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Synthesis and biological evaluation of 2-(5-substituted-1-((diethylamino)methyl)-2-oxoindolin-3-ylidene)-
Topics: | 2013 |
Opportunistic infections of the esophagus not responding to oral systemic antifungals in patients with AIDS: their frequency and treatment.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Administration, Oral; Adult; Amphotericin B; Antifungal Agents; Drug Resistance, Microbial; Esophagitis; Female; Fluconazole; Ganciclovir; Humans; Infusions, Intravenous; Ketoconazole; Male; Opportunistic Infections; Prospective Studies; Treatment Outcome | 1991 |
Clinical aspects of HIV and AIDS.
Topics: Acquired Immunodeficiency Syndrome; Fluconazole; Ganciclovir; HIV Infections; Humans; Opportunistic Infections; Pentamidine | 1990 |
Ganciclovir/acyclovir and fluconazole prophylaxis after simultaneous kidney-pancreas transplantation.
Topics: Acyclovir; Administration, Oral; Antifungal Agents; Antiviral Agents; Fluconazole; Ganciclovir; Humans; Injections, Intravenous; Kidney Transplantation; Opportunistic Infections; Pancreas Transplantation | 1998 |
[Factors causing renal failure in patients with disseminated lupus erythematosus: description of three cases].
Topics: Adult; Antifungal Agents; Antiviral Agents; Candidiasis; Female; Fluconazole; Ganciclovir; Herpes Zoster; Humans; Kidney Failure, Chronic; Lupus Erythematosus, Systemic; Opportunistic Infections; Renal Dialysis; Risk Factors | 1999 |
Preventing opportunistic infections.
Topics: Acyclovir; AIDS-Related Opportunistic Infections; Clarithromycin; Clindamycin; Clinical Trials as Topic; Clotrimazole; Cytomegalovirus Infections; Dapsone; Fluconazole; Ganciclovir; Humans; Itraconazole; Leucovorin; Mycobacterium avium-intracellulare Infection; Mycoses; Pentamidine; Pneumonia, Pneumocystis; Pyrimethamine; Rifabutin; Toxoplasmosis; Trimethoprim, Sulfamethoxazole Drug Combination; Valacyclovir; Valine | 1995 |
[Remission of severe disease induced by CMV and lymphoproliferative post-transplant disease after changing the immunosuppressive regime].
Topics: Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Epstein-Barr Virus Infections; Fluconazole; Ganciclovir; Herpesvirus 4, Human; Humans; Immunocompromised Host; Immunosuppression Therapy; Kidney Transplantation; Lymphoproliferative Disorders; Male; Middle Aged; Postoperative Complications; Tacrolimus | 2002 |
Pharmacokinetics of fluconazole and ganciclovir as combination antimicrobial chemotherapy on ECMO: a case report.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antifungal Agents; Antiviral Agents; Candida albicans; Candidiasis; Cytomegalovirus; Cytomegalovirus Infections; Drug Therapy, Combination; Extracorporeal Membrane Oxygenation; Fluconazole; Ganciclovir; Humans; Male; Respiratory Insufficiency | 2021 |